LimmaTech Biologics AG’s Post

We just announced positive interim results from our Phase I/II clinical trial evaluating Shigella4V, a tetravalent bioconjugate vaccine. This vaccine is designed to protect against shigellosis, which is caused by the Shigella bacterium and is one of the leading causes of diarrheal death, particularly in low- and middle-income countries. With the emergence of multi-drug-resistant strains in recent years, there is a growing need for options that can both protect and address antimicrobial resistance. Our S4V vaccine candidate has shown a favorable safety and tolerability profile. It holds the potential to not only prevent this potentially life-threatening infection in children but also to offer protection to travelers and military personnel visiting Shigella-endemic countries. #Vaccines #AntimicrobialResistance   Find the full press release here: https://bit.ly/3UPbBFb